The firm presented data at the European Society for Medical Oncology Virtual Congress last weekend showing how its method could identify signs of early-stage cancers.
Epic may also develop a liquid biopsy test combining the chromosomal instability biomarker with other markers to predict prostate cancer treatment response.
The "EV Click Chip" process involves collecting and purifying extracellular vesicles from a blood sample before performing RT-ddPCR to identify up to 10 early-stage HCC biomarkers.
The method, called jagged end analysis by sequencing and developed by a team in Hong Kong, relies on DNA end repair with methylated or unmethylated cytosine.
The San Diego-based firm anticipates launching an LDT for early-stage lung cancer out of a CLIA-certified, CAP-accredited lab within the next two years.
IncellDx is also developing a suite of COVID-19 diagnostic products to answer long-term questions about the treatment of patients still suffering from the disease.
Belgium's OncoDNA believes that IntegraGen's bioinformatics platform will help it manage more cancer patient data and quickly generate patient-specific treatment reports for clinicians.
